ARID1A/BAF250a is significantly overexpressed in primary invasive breast cancer

Łukasz Szpon; Anil Agrawal; Michal Jelen; Artur Lipinski; Jerzy Rudnicki; Sebastian Makuch; Marta Woźniak; Mateusz Szmit; Siddarth Agrawal

doi:10.21037/tcr-19-2422

ARID1A/BAF250a is significantly overexpressed in primary invasive breast cancer

Transl Cancer Res. 2020 Jun;9(6):3937-3945. doi: 10.21037/tcr-19-2422.

Authors

Łukasz Szpon¹, Anil Agrawal¹, Michal Jelen², Artur Lipinski², Jerzy Rudnicki³, Sebastian Makuch⁴, Marta Woźniak⁴, Mateusz Szmit³, Siddarth Agrawal^{4

5}

Affiliations

¹ Second Department and Clinic of General and Oncological Surgery, Wroclaw Medical University, Wroclaw, Poland.
² Department of Pathology and Oncological Cytology, Wroclaw Medical University, Wroclaw, Poland.
³ Department of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Wroclaw, Poland.
⁴ Department of Pathology, Wroclaw Medical University, Wroclaw, Poland.
⁵ Department and Clinic of Internal Medicine, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.

Abstract

Background: ARID1A (also known as BAF250a, p270 or SMARCF1) is a major component of the mammalian SWI/SNF family that is involved in the regulation of the chromatin structure. ARID1A gene mutations have been associated with many types of malignancies, including breast cancer. This study aimed to explore the expression of BAF250a protein in breast cancer and its association with the clinical and pathological characteristics and prognosis of breast cancer.

Methods: We assessed the BAF250a expression in 119 invasive breast carcinomas samples and 92 healthy control and correlated this expression pattern with various clinical and pathologic parameters including histologic type and grade, tumor size, lymph node status, estrogen receptor (ER) status, progesterone receptor (PR) status. Immunohistochemical analysis of BAF250a, ER, PR, was carried out, and evaluation of stainings was performed.

Results: The mean value of BAF250a expression in the experimental group was higher than in healthy control (P=0.001). The expression is unrelated to age, menopausal status, lymph node status, tumor size and location, grade and histologic type of tumor, and hormonal status (ER, PR).

Conclusions: These data suggest that BAF250a is overexpressed in breast cancers. BAF250a may play context-dependent tumor-promoting and tumor-suppressive roles in cancer.

Keywords: ARIDI1A/BAF250a; biomarker; breast carcinoma; immunohistochemistry; prognosis.